Skip to main content
. Author manuscript; available in PMC: 2010 May 19.
Published in final edited form as: Circulation. 2009 May 4;119(19):2545–2552. doi: 10.1161/CIRCULATIONAHA.108.844506

Table 4.

Percent increase in mean LVMI and odds ratio of LVH per 1 SD increase in log FGF-23 adjusted for medication use and serum concentrations of CRP, BNP, and 1,25(OH)2D in 162 CKD subjects.

% increase in mean LVMI (95% CI)
per 1 SD increase in log FGF-23		 OR (95% CI) of LVH per 1
SD increase in log FGF-23
Unadjusted model 12% (4%, 18%, P < 0.001) 2.0 (1.2, 3.4, P = 0.006)
Multivariable-adjusted model* 11% (3%, 18%, P = 0.01) 2.3 (1.2, 4.2, P = 0.01)
+ active vitamin D use 11% (4%, 18%, P = 0.005) 2.2 (1.2, 4.3, P = 0.01)
+ phosphorus binder use 11% (4%, 18%, P = 0.003) 2.2 (1.2, 4.2, P = 0.01)
+ log CRP 11% (3%, 18%, P = 0.005) 2.3 (1.2, 4.2, P = 0.01)
+ log BNP 11% (5%, 16%, P = 0.006) 2.3 (1.1, 4.6, P = 0.01)
+ 1,25(OH)2D† 10% (4%, 18%, P = 0.003) 2.0 (1.4, 3.0, P = 0.008)
*

adjusted for age, gender, race, BMI, eGFR, diabetes, hypertension, and serum phosphate.

†

1,25(OH)2D was measured in 69 subjects; therefore, 1,25(OH)2D was analyzed as a categorical variable with a separate category for missing values.

FGF-23, fibroblast growth factor 23; LVMI, left ventricular mass index (g/m2.71); LVH, left ventricular hypertrophy; SD, standard deviation; CRP, c-reactive protein; BNP, B-type natriuretic peptide; 1,25(OH)2D, 1,25-dihydroxyvitamin D; CKD, chronic kidney disease.